BitWats release Powerful 5nm ASIC Miners

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) — Bitwats (www.BitWats.com), a team of technology leaders working relentlessly to bring the latest crypto–mining technology to the public, has just released the market's most powerful and profitable crypto miners. The company's product range currently comprises of BT, DBT, and GBT, three multi–algorithm miners capable of delivering lightening fast hash rate, maximum energy efficiency, and fastest possible return on investment.

All the miners from Bitwats are built around the latest ASIC technology. An ASIC or application–specific integrated circuit is a microchip designed for a special application. Powered by 5nm ASIC chips, the mining rigs from Bitwats offer extraordinary hash rates and energy efficiency for mining bitcoin, litecoin, ethereum, and monero. As a result, the profitability of these miners is second to none in the current crypto market.

DBT offers hash rates of 750 TH/s, 70 GH/s, 5 GH/s, and 5 MH/s, for bitcoin, litecoin, ethereum, and monero respectively. On the other hand, for GBT Miner, the hash power in the same order are 2250 TH/s, 210 GH/s, 15 GH/s, and 15 MH/s. The power consumptions for these two units are 900W and 2200W respectively

Bitwats designed its crypto miners with the goal of making crypto mining easy and profitable for all, including the newbies. Once these miners are delivered, anyone can start mining simply by connecting the unit to a power socket and accessing it through WiFi or cable, and entering the pool data. Users also have the option of joining Bitwats' own mining pool that has a 0% fee. Also, the company covers the delivery and custom fees for its customers.

To find out more, please visit https://www.bitwats.com

About Bitwats: Bitwats was founded in 2016 by a team of technology leaders with a track record of working for the world's most prodigious companies in the past. Dedicated to bringing the latest crypto–mining technology to the public, the company has recently introduced its exquisite line of advanced ASIC miners. Unlike most other crypto mining hardware manufacturers, Bitwats continuously works towards making crypto mining easy and profitable for all regardless of their experience and knowledge.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3e97db4–cc4e–4348–9ef5–48fb7acc0b0f

Contact:
Daniel Lotin
marketing@bitwats.com
+1 (347) 905–5614


GLOBENEWSWIRE (Distribution ID 8220346)

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

BRUSSELS, Belgium and MELBOURNE, Australia, April 20, 2021 (GLOBE NEWSWIRE) — The Oncidium Foundation, a non–profit organisation created to promote and support the development of radiopharmaceuticals for better patient access, and Telix Pharmaceuticals Limited ("Telix'), a radiopharmaceutical company developing diagnostic and therapeutic products ("theranostics') using Molecularly Targeted Radiation (MTR), are pleased to announce the launch of the NOBLE Registry, an international clinical collaboration for the development of 99mTc–iPSMA SPECT imaging for prostate cancer, and the dosing of the first patient at the University College Hospital, Ibadan, Nigeria.

Prostate cancer is the second most frequent cancer diagnosis in men and the fifth leading cause of cancer death worldwide1. Early detection can significantly reduce the mortality rate and in recent years much attention has focused on PSMA2 as a target for imaging and therapy using radionuclides for prostate cancer.

PSMA positron emission tomography (PSMA PET) is an emerging standard of care in prostate cancer imaging.3 Unfortunately, globally, not every patient will have access to a PSMA PET scan when indicated. The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost–effective and viable alternative. Enhancing global availability and access to 99mTc–iPSMA SPECT imaging has the potential to provide accurate diagnosis and staging to patients with prostate cancer regardless of where they reside.

The NOBLE Registry Committee, made up of globally recognized investigators at eight sites worldwide,5 aims to deliver and publish real–world evidence and clinical practice guidelines related to SPECT imaging and prostate cancer.

"The advancement of PSMA directed diagnostics and therapeutics in prostate cancer is helping to extend life and improve treatment outcomes in men with prostate cancer," said Dr. Batool Albalooshi, Chair of the NOBLE Registry Committee. "However, millions of men do not have access to PET imaging. For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA SPECT technology."

"Introducing PSMA has been difficult and exciting for the team at Ibadan. When I think of the opportunities for prostate cancer research and management without PET, I am motivated to get past the challenges. I look forward to a better future, with nobody left behind," said Dr. Akintunde Orunmuyi, Investigator at the University College Hospital, Ibadan, Nigeria, where the first patient is being dosed.

The NOBLE Registry has been initiated and is co–supported by the Oncidium Foundation and Telix Pharmaceuticals. "We aim to enable patients with prostate cancer, regardless of origin, technology access or financial situation, to access PSMA SPECT imaging for accurate diagnosis and treatment planning," said Rebecca Lo bue, General Manager of the Oncidium Foundation.

"We are honoured to support the launch of the NOBLE Registry, which represents the very essence of our belief that every patient deserves access to the benefits of nuclear medicine. We wish to thank the Oncidium Foundation for their support and partnership, as well as the expert global clinical leadership team led by Dr. Albalooshi. Above all, we are grateful to the patients that will make this registry study possible and, in doing so, help to deliver an important milestone toward improving access to this important technology." said Dr. Christian Behrenbruch, Chief Executive Officer of Telix Pharmaceuticals.

About the Oncidium Foundation
The Oncidium Foundation was created in 2011 by Dr. Richard Zimmermann. The Foundation's priorities include promoting awareness about radiotherapeutics among patients and physicians, investing in research and scholarships, supporting, and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients. https://www.oncidiumfoundation.org/

About Telix Pharmaceuticals Limited

Telix is a clinical–stage radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical–stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.

None of Telix's products have received a marketing authorisation in any jurisdiction.

Oncidium Foundation Contact Telix Media Contact
Rebecca Lo bue
Oncidium Foundation
General Manager
Email: rebecca@oncidium–life.org
Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director of Corporate Communications
Email: Stewart.Holmstrom@Telixpharma.com

_______________________

1 Globocan 2020.
2 Prostate–specific membrane antigen – a protein expressed on the surface of prostate cancer cells.
3 Hofman M, et al. The Lancet 2020; Trabulsi E, et al. Journal of Clinical Oncology 2020.
4 In 2020 there were an estimated 25,500 SPECT and 6,700 PET cameras installed worldwide (Source: MEDraysintell).
5 Australia, Egypt, India, Mexico, Nigeria, South Africa, Turkey, United Arab Emirates.


GLOBENEWSWIRE (Distribution ID 8220274)

Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010, and was Chairman from 2014 to 2016.

Mr. Mayron is global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben–Gurion University, an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major.

Jerry Lieberman, Entera's Chairman commented, "We welcome Ron to the Board as we advance our pipeline of oral drug candidates for biologics and active ingredients that were previously only administrated through injection. Ron's deep knowledge in the management and logistics of commercialized pharma products at Teva, as well as his vast experience serving on the boards of over a dozen private and publicly traded healthcare companies are assets to Entera."

"On behalf of the entire Board, I extend gratitude to Zeev for his insight as a Founder of Entera, his leadership as a Board member, and his twelve years of service to the Company. His contributions have helped Entera become a NASDAQ listed company and a global leader in the oral delivery of proteins. We wish him well," Mr. Lieberman concluded.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the complete3–month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA's interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Annual Report on Form 20–F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.

Contact:

Spiros Jamas, CEO
Tel: +001 617–362–3579
spiros@enterabio.com


GLOBENEWSWIRE (Distribution ID 8220199)